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Abstract
Background There is growing evidence that memantine, a
noncompetitive N-methyl-D-aspartate receptor antagonist,
may be applied as an add-on in treating patients suffering
from obsessive–compulsive disorders (OCD). The aim of
the present study was therefore to assess the effect of adju-
vant memantine in a double-blind, randomized, and
placebo-controlled study of the treatment of patients suffer-
ing from OCD.
Method A total of 40 inpatients (32 females (80 %); mean
age=31.25 years) suffering from OCD were randomly
assigned to a treatment (administration of memantine) or a
control group (placebo). Treatment lasted for 12 consecutive
weeks. All patients were treated with selective serotonin re-
uptake inhibitors or clomipramine. Patients completed the
Yale–Brown Obsessive Compulsive Scale four times.
Experts’ ratings consisted in clinical global impression
(clinical global impressions (CGI), illness severity and ill-
ness improvement; two to three times). Liver enzymes
SGOT and SGPT were also assessed (twice).
Results Of the 40 inpatients approached, 29 completed the
12 consecutive weeks of the study. Of the 11 dropouts, 6
were in the target group and five in the control group.
Symptoms significantly decreased across the period of the
study, but particularly in the treatment compared with the
control group (significant time×group interaction). Illness
severity (CGI severity) also significantly decreased over
time but more so in the treatment than in the control group
(significant time×group interaction). Illness improvements
(CGI improvements) were not significant.
Conclusions The pattern of results from the present double-
blind, randomized, and placebo-controlled study for the
treatment of patients suffering from OCD suggests that
adjuvant memantine does significantly and favorably impact
on OCD.
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Introduction
Worldwide, 1 to 3 % of the population suffers from obses-
sive–compulsive disorders (OCD) (Kessler et al. 2005;
Ruscio et al. 2010; Karno et al. 1988). Symptoms of OCD
include persistent intrusive thoughts (obsessions), repetitive
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and ritualistic behaviors (compulsions), and excessive anx-
iety (Diagnostic and Statistical Manual of Mental Disorders
4th edition, text revision (DSM-IV-TR), APA 2000).
Suffering from OCD is associated with dramatically de-
creased quality of life and increased risk of deteriorated
social interactions and loss of employment, accompanied
therefore with a high risk of disability and morbidity
(Hollander 1996).
Treatment of OCD is via psychopharmacological and
psychotherapeutic interventions. Cognitive-behavioral ther-
apy is as effective as psychopharmacological interventions
(Franklin and Foa 2011), though patients suffering from
OCD are generally treated psychopharmacologically, and,
specifically, with selective serotonin re-uptake inhibitors
(SSRIs) and clomipramine, a tri-cyclic antidepressant (cf.
Wu et al. 2012). Both psychopharmacological and psycho-
therapeutic interventions are successful in 40 to 70 % of
cases (Foa et al. 2005; Swedo and Snider 2004), though
residual symptoms without full remission are often observed
(Ackerman and Greenland 2002; Mataix-Cols et al. 2002),
again increasing the risk for disability and morbidity
(Hollander 1996).
Results from twin studies suggest a genetic basis to OCD
(Hanna et al. 2005; Hettema et al. 2001; van Grootheest et al.
2005), with heritability estimates for OCD symptoms in chil-
dren between 45 and 65 % (van Grootheest et al. 2005).
Additionally, a growing body of evidence has shown that
changes in glutamate levels and distribution seem to be key
to the development and maintenance of OCD symptoms (see
Wu et al. 2012; Ghaleiha et al. 2013; Stewart et al. 2010 for
extensive overview). That is to say, disruption to glutamatergic
transmission, the main excitatory transmitter in the brain, has
been observed both in human and animal studies as a key
factor in production of OCD symptoms. Consequently, a
search for substances indirectly regulating glutamate receptors,
for example, memantine, a noncompetitive N-methyl-D-aspar-
tate (NMDA) receptor antagonist, has become the focus of
research in the psychopharmacological treatment of OCD
(Afshar et al. 2012; McGrath et al. 2000; Wu et al. 2012).
Memantine is a nonncompetitive NMDA receptor antagonist
reducing glutamatergic excitotoxicity and thus protecting
against the excitotoxic destruction of cholinergic neurons (cf.
Pasquini and Biondi 2006). Poyurovsky et al. (2005) reported
the first successful treatment with memantine augmentation in
a single case study while Pascquini and Biondi (2006) reported
two cases of patients suffering from OCD, with and without
success with memantine augmentation. Hezel et al. (2009)
reported an effective treatment of a 15 years old girl suffering
from severe OCDwith memantine augmentation. Stewart et al.
(2010) applied a single-blind case–control study to exploring
the influence of memantine augmentation in 38 out-patients
suffering from OCD; to our knowledge, Stewart et al. (2010)
were among the first to demonstrate the symptom improving
effects of memantine augmentations in patients suffering from
OCDwhile performing a single-blind case–control study.Most
recently, Ghaleiha et al. (2013) were also able to prove, in a
randomized, double-blind, placebo-controlled study, that the
application of memantine add-on was significantly associated
with improved short-term outcomes in patients suffering from
moderate to severe OCD. Patients were about 37 years old, and
the study lasted for eight consecutive weeks.
The aim of the present randomized, double-blind, and
placebo-controlled study was to further prove the effective-
ness of memantine add-on in the treatment of patients suf-
fering from OCD and in this case around 31 years of age,
and, unlike the study by Ghaleiha et al. (2013) in which
treatment was for eight consecutive weeks, with a period of
observation of 12 weeks.
Following Stewart et al. (2010) and Ghaleiha et al. (2013),
we hypothesized that memantine add-on in patients suffer-
ing from severe OCD would be associated with significant
symptom improvements.
Method
Study design and randomization
The present study was a 12-week, randomized, double-blind,
placebo-controlled clinical trial. Patients suffering from OCD
were recruited between September 2009 and September 2010
in the Farshchian Hospital of Hamadan (Iran). Prior to ran-
domization, a total of 40 boxes were prepared and numbered
from 1 to 40; of these boxes, 20 contained memantine tablets
(verum) and 20 contained placebo. Staff responsible for pack-
aging and preparation of the boxes was not further involved in
the study. To number the boxes, randomization was achieved
via a computerized random number generator. Next, 40 raffle
tickets were numbered from 1 to 40, put in a ballot box and
stirred. At the start of the study, patients drew a raffle ticket
and were assigned the box with the matching number. Patients
thus received either verum (memantine 5–10 mg/day) or
placebo (5–10 mg/day). Neither patients nor study nurses
and study physicians were informed of group assignments.
Verum and placebo were given as tablets with identical shape
and color, and the packaging of both compounds was likewise
identical. One week before starting the study and throughout
the study, patients were treated with a standard SSRI or
clomipramine at therapeutic dosages for at least 12 consecu-
tive weeks.
Sample
A total of 40 inpatients suffering from OCD (32 females
(80 %); mean age, M=31.25, SD=5.06) were approached
and diagnosed according the Diagnostic and Statistical
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Manual of Mental Disorders 4th edition, text revision
(DSM-IV-TR) criteria (American Psychiatric Association
2000). Patients were fully informed about the study aims
and procedure, and about the confidential nature of data
selection and data handling, and gave their written informed
consent. The study took place in the psychiatric ward of the
Research Center for Behavioral Disorders and Substances
Abuse (Frashchian Hospital; Hamadan University of
Medical Sciences, Hamadan, Iran). The local ethics com-
mittee approved the study, and the entire study was
performed in accordance with the ethical standards laid
down in the Declaration of Helsinki.1
Inclusion criteria
Patients were enrolled in the study if the following inclusion
criteria were met: (1) diagnosis by a psychiatrist of current
OCD according to the DSM-IV-TR (American Psychiatric
Association 2000). (2) Yale–Brown Obsessive Compulsive
Scale (Y-BOCS) score of 21 points or higher (see below).
(3) No comorbid psychiatric disorders. (4) No systemic
disorders such as diabetes, hypertension, hyper- or hypothy-
roidism. (5) No alcohol and other drug use. (6) Age between
18 and 40 years. (7) Medication 1 week prior to the begin-
ning of the study (and continued throughout the study) of an
SSRI (e.g., escitalopram, 10 mg/day; citalopram, 30-
50 mg/day) or clomipramine (100–175 mg/day) at therapeu-
tic dosages for at least 12 consecutive weeks (see also
Table 1).
Exclusion criteria
Patients were not enrolled in the study if: (1) the
abovementioned inclusion criteria were not met; (2)
female participants were pregnant or breast-feeding or
intended to become pregnant during the period of the
study; (3) there was a history of memantine use.
Patients were removed from the study if: (4) adverse
effects were reported or observed; (5) the liver enzymes
SGOT and SGPT increased more than threefold com-
pared with baseline levels; and (6) patients indicated to
withdraw from the study.2
Of the 40 inpatients approached, 29 completed the study;
of the 11 dropouts (six in the target group and five in the
control group), 9 patients (five in the target and four in the
control group) withdrew from the study within the first
2 weeks without further justification and 2 (one patient for
each group) reported side-effects between the second and
eighth weeks (light-headedness and vertigo3).
Descriptive and statistical comparisons of the target and
control groups are reported in Table 1. At baseline, target
and control groups did not differ with respect to gender,
medication (SSRI or clomipramine), age, or symptom se-
verity (Y-BOCS; see below).
Tools
Assessing OCD with the Y-BOCS
The Y-BOCS (Goodman et al. 1989) consists of ten items and
answers are given on 5-point Likert scales ranging from
0 (lowest severity) to 4 (highest severity), with higher sum
scores reflecting more severe OCD (Cronbach’s alpha=0.89).
The Y-BOCS was completed four times; at the beginning
of the study, after 4, 8, and 12 weeks, that is, at the end of
the study.
Assessing changes in illness severity and improvement
Illness severity was assessed with the clinical global impres-
sions (CGI; Guy 1976). This consists of one item asking
how mentally ill a patient is currently. Answers are given on
a 7-point Likert rating scale ranging from 1 (normal; not at
all ill) to 7 (among the most extremely ill patients), a higher
score therefore reflecting greater illness severity. Illness
severity was assessed three times; after 4 and 8 weeks, and
after 12 weeks, that is, at the end of the study.
Treatment improvement was likewise assessed with the
CGI. The item asks about global improvement, and answers
are given on a 7-point Likert rating scale ranging from 1
(very much improved) to 7 (very much worse), a higher
score thus reflecting greater deterioration in condition.
Illness improvement was assessed two times; after 8 and
12 weeks, that is, at the end of the study.
Statistical analyses
Demographic and symptom characteristics were compared
at baseline between the target and control group with a Chi-
square test and with single t tests. A series of ANOVAs for
repeated measures was performed with the factors Time (4
time points for Y-BOCS scores; 3 time points for CGI
severity scores, and 2 time points for CGI improvement
1 The clinical trial number is: IRCT138712141743N1; www.irct.ir.
2 In the latter case, in strict accordance with the declaration of Helsinki,
patients were free to withdraw from the study without any further
justification or explanation. Moreover, they were assured that with-
drawing from the study without any further justification was in no way
associated with any disadvantages.
3 Once a week, patients received a list indicating possible side-effects
due to adjuvant medication (answers; yes/no). The list was based on
the Joint Formulary Committee (2004) and comprised the following
side-effects: confusion, dizziness, drowsiness, headache, insomnia,
agitation and/or hallucinations, vomiting, light-headedness, vertigo,
and anxiety.
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scores) and group (memantine vs. placebo), and the depen-
dent variables Y-BOCS scores, CGI severity scores, and
CGI improvement scores. Where appropriate, post hoc tests
with the Bonferroni–Holm correction for p values were
used, applying single t tests. To compensate for any de-
viations from sphericity, statistical tests were performed
using Greenhouse–Geisser corrected degrees of freedom,
though throughout the paper the original degrees of freedom
are reported with the relevant Greenhouse–Geisser epsilon
value (ε). For ANOVAs, effect sizes were indicated with the
partial eta squared (η2), with 0.059≥η2≥0.01 indicating
small (S), 0.139≥η2≥0.06 indicating medium (M), and
η2≥0.14 indicating large (L) effect sizes (Cohen 1988).
Based on Pallanti and Quercioli (2006), the following
categorizations of treatment response were calculated, based
on the percentage of the Y-BOCS score reduction. Pallanti
and Quercioli (2006) proposed a threshold of 35 % or more
in Y-BOCS reduction for “full response.” 25–35 % for
“partial response,” and less than 25 % for “no response.”
The level of significance was set at p≤0.05, and all
statistics were processed using SPSS® 19.0 for Apple
McIntosh®.
Results
Changes in OCD symptoms (Y-BOCS scores)
Table 2 gives the descriptive and statistical overview for the
Y-BOCS scores over four time points and separately for the
target and the control groups.
Y-BOCS scores decreased significantly over time; Y-
BOCS scores did not differ between the two groups. The
time by group interaction showed that Y-BOCS scores sig-
nificantly decreased over time in the target as compared
with the control group.
Considering the groups separately, single post hoc anal-
yses with Bonferroni–Holm corrections for p-values showed
that in the control group YBOCS values at the first time
point differed significantly from those at the third and fourth
time points. For the target group, no difference was ob-
served between the YBOCS-values at the first and the
second time points; YBOCS values at the second time point
did differ significantly from the third and fourth time points,
and those at the third time point did significantly differ from
the fourth time point. Post hoc analyses suggested that in the
treatment group a continuous decrease could be observed
(see Fig. 1)
Y-BOCS response rates (categorizations) and group
allocation
Following Pallanti and Quercioli (2006), the following
thresholds were calculated: 35 % or more in Y-BOCS re-
duction for “full response,” 25–35 % for “partial response,”
and less than 25 % for “no response.”
Table 3 gives the descriptive and statistical overview for
the Y-BOCS categorizations over three time points and
separately for the target and control groups.
As shown in Table 3, after 12 weeks of treatment, full
response was significantly more likely in the target than in
the control group.
CGI symptom severity
Table 4 gives the descriptive and statistical overview for the
CGI symptom severity scores over 3 time points and sepa-
rately for the target and control groups.
CGI severity decreased significantly over time. CGI se-
verity did not differ between the target and the control
group. The time by group interaction showed that CGI
severity scores significantly decreased over time in the
Table 1 Descriptive and statistical overview of sample characteristics (age, gender, symptom severity, and duration of illness) at baseline between
the target group (memantine) and control group (placebo)
Groups Statistics
Target groupa (N=14) Control groupb (N=15) t(27) χ2(N=29, df=1) p
Age (years; mean and standard deviation) 30.78 (6.00) 31.60 (5.09) 0.39 0.69
Gender (m/f) 2/12 4/11 0.67 0.41
Medication (SSRI/clomipramine) 11/3 11/4 0.11 0.71
Duration of illness (years) 4.05 (1.99) 3.75 (1.45) 0.92 0.36
Y-BOCS at baseline (M, SD) 28.86 (4.87) 28.13 (3.48) 0.46 0.65
Description and statistics only for study completers (N=29)
Y-BOCS Yale–Brown Obsessive Compulsive Scale
aWith memantine add-on
b Placebo
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target as compared with the control group. Considering the
groups separately, single post hoc analyses with Bonferroni–
Holm corrections for p values showed that in both the target
and the control group CGI severity at the first time point
differed significantly from those at the second and third time
points. Therefore, post hoc analyses suggested that
irrespective of group, CGI illness severity showed a pro-
gressive decline (see Fig. 2).
CGI improvements
Table 4 also gives the descriptive and statistical overview
for the CGI improvement scores over two time points and
separately for the target and control groups.
CGI improvement scores did not significantly change over
time or differ as between the target and the control group.
Discussion
The key findings of the present double-blind, placebo-
controlled and randomized trial were that inpatients suffer-
ing from OCD improved significantly after 12 weeks with
adjuvant memantine to standard SSRI or clomipramine
medication as compared with patients with adjuvant place-
bo. The findings add to the current literature in so far as we
were able to show in a double-blind, randomized, and
placebo-controlled study design that adjuvant memantine
reduces illness in inpatients suffering from OCD.
Following Stewart et al. (2010) and Ghaleiha et al. (2013),
we expected symptom improvements in patients suffering
from OCD with adjuvant memantine, relative to patients with
placebo, and the data did fully support this expectation. In this
regard, the present findings do support the most recent, though
rather scarce data regarding OCD symptom improvements
with NMDA receptor antagonists. Most importantly, while
the response of patients in the placebo group, that is, in the
SSRI or clomipramine monotherapy, was within the expected
range (cf. Goodman et al. 1996; Pigott and Seay 1999),
adjuvant memantine led to significantly more full responders
(see Table 3). In this respect, the present pattern of results add
to the current literature in so far as we were able to
demonstrate a successful application of adjuvant memantine
as an NMDA receptor antagonist with patients suffering from
severe OCD.
Most importantly, as the data indicate (see Table 2; Fig. 1),
significant improvements were observed in the target group
only after 8 to 12weeks, suggesting that a time lapse of at least
12 weeks may be necessary to observe marked improvement.
Additionally, in contrast to Ghaleiha et al. (2013) who
employed a time lapse of 8 weeks and speculated that perhaps
the study period was too short to observe greater improvement
in the monotherapy group, we note that in the present study
after 12 weeks of treatment, no further improvements could be
observed in the monotherapy group with standard SSRIs or
clomipramine. As a result, based on the present pattern of
results, we believe that a monotherapy with standard SSRIs or
clomipramine leads to (modest) improvements within the first
8 weeks of treatment, while an add-on therapy with
memantine produces increased efficacy but after 12 (or more)
weeks. In this regard, unlike the results of Ghaleiha et al.
(2013), we propose that adjuvant memantine not only accel-
erates the monotherapy response, but also affects the overall
response rate.
Table 2 Descriptive and statistical overview of the Yale–Brown Obsessive Compulsive Scale scores for four time points (baseline, after 4, 8, and











28.86 (4.87) 28.78 (3.98) 24.65 (4.25) 19.57 (3.76) Time: F(3, 81)=26.32, p=0.000, η2=0.49 (L)
Group: F(1, 27)=0.21, p=0.65, η2=0.008 (S)
Control group (placebo) 28.13 (3.48) 26.07 (5.20) 26.00 (2.70) 23.67 (3.56) Time by group interaction: F(3, 81)=6.09,
p=0.005, η2=0.18 (L)
Greenhouse–Geisser epsilon value (ε)=0.64
Fig. 1 Y-BOCS scores decreased over time, and above all in the target
group (memantine; statistically significant time by group interaction)
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As possible explanations for the favorable effect of
memantine on patients suffering from OCD, several lines of
evidence suggest an underlying glutamatergic dysfunction in
the pathophysiology of OCD (cf. Rosenberg and Keshavan
1998; Saxena et al. 2001; Wu et al. 2012), with, specifically,
evidence from cerebrospinal fluid studies. Chakrabarty et al.
(2001) investigated cerebrospinal fluid from 21 patients suf-
fering from OCD and 18 controls and showed that irrespective
of gender, age or illness history, glutamate concentrations were
significantly higher in the OCD as compared with the control
group, a pattern of results replicated by the same research team
with further patients and controls (Bhattacharyya et al. 2009).
Moreover, whereas a balance between direct and indirect path-
ways in the corticostriatal–thalamocortical circuitry reflects
pathophysiologically favorable processes, it is assumed that a
hyperactivity of the direct pathway and/or hypoactivity of the
indirect pathway leads to a disinhibition of this circuitry with
an ultimate effect on compulsions and obsessions (Rosenberg
et al. 2000, 2004; Yücel et al. 2008). Specifically, based on
proton magnetic resonance spectroscopy, Rosenberg et al.
(2000), Starck et al. (2008), and Yücel et al. (2008) were able
to show, in patients suffering from OCD, greater left, but not
right caudate glutamatergic concentrations, as well as lower
anterior cingulate cortex (ACC) glutamate concentrations.
Whiteside et al. (2006) reported greater orbital frontal
glutamatergic concentrations in patients with OCD as com-
pared with controls. As an overall concept, Rosenberg et al.
(2004) claimed that a possible dysregulation of glutamate
within cortico-striatal circuitry with reduced glutamate in the
ACC, and a glutamate overactivity in the striatum and
orbitofrontal cortex may be the underlying glutamatergic pro-
cess in OCD. Additionally, a broad variety of further glutamate
post-synaptic signaling dysfunctions (Ting and Feng 2011) and
genetic causes (see Wu et al. 2012 for extensive overview; see
Table 3 Descriptive and inferential statistics of response rates of the Yale–Brown Obsessive Compulsive Scale (Y-BOCS), separately by target and
control group
Second time point (after 4 weeks) Third time point (after 8 weeks) Fourth time point (after 12 weeks)
Response Response Response
Full Partial No Full Partial No Full Partial No
Target group 0 0 20 1 0 13 9 4 1
Control group 1 3 16 0 0 15 0 4 11
Statistics χ2 χ2(N=40, df=2)=4.44, p=0.10 χ2(N=29, df=1)=1.11, p=0.129 χ2(N=29, df=2)=9.24, p=0.01
Notes: Full response=−35 % or more of Y-BOCS scores compared with baseline; partial response=−25 to −34 % of Y-BOCS scores compared with
baseline; no response=≤25 % of Y-BOCS scores compared with baseline
Table 4 Descriptive and statistical overview of the Clinical Global
Impression Severity scores for three time points (after 4, 8, and
12 weeks (end of the study)) and of the Clinical Global Impression
Improvement scores (after 8 and 12 weeks (end of the study)) sepa-












– 4.71 (0.73) 4.21 (0.70) 3.29 (0.61) Time: F(2, 54)=20.27, p=0.000, η2=.43 (L)
Group: F(1, 27)=0.40, p=0.53, η2=0.015 (S)
Control group
(placebo)
– 4.47 (0.99) 4.27 (0.70) 3.87 (0.64) Time by group interaction: F(2, 54)=3.36,
p=0.044, η2=0.11 (M)





– – 2.86 (0.86) 2.50 (0.65) Time: F(1, 27)=1.75, p=0.20, η2=0.061 (S)
Group: F(1, 27)=1.06, p=0.31, η2=0.038 (S)
Time by Group interaction: F(1, 27)=0.36, p=0.55,
η2=0.013 (S)
Control group (placebo) – – 2.93 (0.70) 2.80 (0.56)
CGI clinical global impression
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Hanna et al. 2005; Hettema et al. 2001; van Grootheest et al.
2005 for results from twin studies) may further explain the
development and maintenance of OCD.
Despite the intriguing findings, several limitations warrant
against their overgeneralization. First, the sample size is rather
small, though we relied more on effect size calculations
which, unlike p-values, are unaffected by sample size.
Second, other psychological dimensions such as depression
and anxiety symptoms were not assessed, and perhaps im-
provements in OCD were merely a result of decreased symp-
toms of anxiety and depression. Third, the study design does
not allow a deeper consideration of molecular processes.
Fourth, likewise, the complex processes of glutamatergic reg-
ulations in various areas of the brain were neither directly, nor
indirectly measured. In this respect, strictly speaking the fact
that memantine as a NMDA receptor antagonist did favorably
improve OCD symptoms does not directly prove that our
theoretical model of the underlying mechanisms is correct.
Rather, it remains possible that the present pattern of results
emerged due to other though unassessed molecular, neuronal,
and psychological processes (see above and below). Fifth, in
this respect, glutamate receptor antagonists are related to an
enhancement of 5-HT2A receptor-mediated transmission and,
following Carlsson (2001), 5-HT2A agonism leads to reduced
glutamatergic transmission while 5-HT receptor activation is
related to a reduction of the excitatory effect of glutamate on
cellular activity (cf. Saxena and Rauch 2000). As a conse-
quence, as already outlined above, it is also conceivable that
the present pattern of results is due to further, though
unassessed pathophysiological processes. Sixth, only patients
suffering from OCD without further comorbidities were in-
cluded, leaving it unclear whether memantine add-on might
be helpful for patients suffering from OCD and a concomitant
broader spectrum of further psychiatric disorders. Notably,
whereas it is usual to sample from comorbidity-free
populations for highly standardized clinical trials, such pa-
tients are the exception rather than the rule within clinical
everyday life. Seventh, the sample consisted of patients suf-
fering from severe OCD for the first time in their lives, and it
remains unclear to what extent memantine add-on might also
be helpful for patients suffering from therapy-resistant and
refractory OCD. Eighth, patients had sociotherapeutic events
and (psychotherapeutic) contact with psychologists, psychia-
trists and hospital nurses though, given that no data were
gathered on these aspects, it remains unclear to what extent
these sociotherapeutic events and (psychotherapeutic) contact
may have favorably influenced the course of illness. However,
irrespective of group assignment, all patients had the same
opportunities to benefit from sociotherapeutic events and
(psychotherapeutic) contacts, and therefore, it seems highly
unlikely that data were systematically biased. Ninth, we note
that after 8 of the 12 weeks, 11 of the 40 patients had dropped
out of the study for different reasons. Therefore, the present
findings should be interpreted in the light of the observed
attrition rate. Last, no insight into cognitive-emotional pro-
cesses was gained, leaving it uncertain to what extent psycho-
pharmacological treatment led to new insights and modified
behavior for coping with symptoms of OCD. Further double-
blind, randomized, and placebo-controlled studies on OCD
might include patients suffering from refractory OCD and
with additional comorbidities, as well as assessing symptoms
of depression and anxiety and, for instance, cognitive-
emotional processes.
Conclusions
Data from the present randomized, double-blind, and
placebo-controlled study suggest that an add-on of
memantine, a noncompetitive NMDA antagonist, does im-
prove the symptoms of patients suffering from severe OCD.
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